Abstract

To date, substantial evidence has shown a significant association between inflammatory bowel diseases (IBD) and development of colitis-associated cancer (CAC). The incidence/prevalence of IBD is higher in western countries including the US, Australia, and the UK. Although CAC development is generally characterized by stepwise accumulation of genetic as well as epigenetic changes, precise mechanisms of how chronic inflammation leads to the development of CAC are largely unknown. Preceding intestinal inflammation is one of the major influential factors for CAC tumorigenesis. Mucosal immune responses including activation of aberrant signaling pathways both in innate and adaptive immune cells play a pivotal role in CAC. Tumor progression and metastasis are shaped by a tightly controlled tumor microenvironment which is orchestrated by several immune cells and stromal cells including macrophages, neutrophils, dendritic cells, myeloid derived suppressor cells, T cells, and myofibroblasts. In this article, we will discuss the contributing factors of epithelial as well as immune cell signaling in initiation of CAC tumorigenesis and mucosal immune regulatory factors in the colonic tumor microenvironment. In depth understanding of these factors is necessary to develop novel anti-inflammatory and anti-cancer therapies for CAC in the near future.

Highlights

  • Colorectal cancer is the second leading cause of mortality in the US and the third most common cancer when men and women are considered separately

  • This review will discuss the characteristics of sporadic colon cancer and CAC, effect of inducible molecules on intestinal epithelial cells (IECs), role of tumor associated immune cells in CAC development, tumor microenvironment, and possible future therapeutics

  • We found that non-hematopoietic lineage, including IECs, is the major source of CHI3L1, which promotes CAC tumorigenesis and epithelial proliferation

Read more

Summary

Introduction

Colorectal cancer is the second leading cause of mortality in the US and the third most common cancer when men and women are considered separately. The American Cancer Society has estimated approximately 93,090 new colon cancer patients in 2015. The association between inflammatory bowel disease (IBD) and colitis-associated cancer (CAC) has been identified about eight decades ago by Drs Burrill Crohn and Herman Rosenberg [1]. CAC contributes to 10-15% of death cases in IBD patients who have long standing (>10 years) and extensive inflammation in the colon. Our current understanding of the pathogenesis of CAC, molecular signaling, and treatment strategies have improved the survival of CAC patients considerably. Much more detailed functional studies are necessary to develop precise treatment strategies for CAC. This review will discuss the characteristics of sporadic colon cancer and CAC, effect of inducible molecules on intestinal epithelial cells (IECs), role of tumor associated immune cells in CAC development, tumor microenvironment, and possible future therapeutics

Sporadic Colon Cancer and Colitis-Associated Cancer
Signaling molecules as therapeutic targets
Findings
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call